These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 18164612)

  • 1. An evaluation of a preparation of Mycobacterium vaccae (SRL172) as an immunotherapeutic agent in renal cancer.
    Patel PM; Sim S; O'Donnell DO; Protheroe A; Beirne D; Stanley A; Tourani JM; Khayat D; Hancock B; Vasey P; Dalgleish A; Johnston C; Banks RE; Selby PJ
    Eur J Cancer; 2008 Jan; 44(2):216-23. PubMed ID: 18164612
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A randomized phase II study of SRL172 (Mycobacterium vaccae) combined with chemotherapy in patients with advanced inoperable non-small-cell lung cancer and mesothelioma.
    O'Brien ME; Saini A; Smith IE; Webb A; Gregory K; Mendes R; Ryan C; Priest K; Bromelow KV; Palmer RD; Tuckwell N; Kennard DA; Souberbielle BE
    Br J Cancer; 2000 Oct; 83(7):853-7. PubMed ID: 10970684
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A randomized phase II trial of SRL172 (Mycobacterium vaccae) +/- low-dose interleukin-2 in the treatment of metastatic malignant melanoma.
    Nicholson S; Guile K; John J; Clarke IA; Diffley J; Donnellan P; Michael A; Szlosarek P; Dalgleish AG
    Melanoma Res; 2003 Aug; 13(4):389-93. PubMed ID: 12883365
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Successful immunotherapy with Mycobacterium vaccae in the treatment of adenocarcinoma of the lung.
    Stanford JL; Stanford CA; O'Brien ME; Grange JM
    Eur J Cancer; 2008 Jan; 44(2):224-7. PubMed ID: 17928219
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mycobacterium vaccae (SRL172) immunotherapy as an adjunct to standard antituberculosis treatment in HIV-infected adults with pulmonary tuberculosis: a randomised placebo-controlled trial.
    Mwinga A; Nunn A; Ngwira B; Chintu C; Warndorff D; Fine P; Darbyshire J; Zumla A;
    Lancet; 2002 Oct; 360(9339):1050-5. PubMed ID: 12383985
    [TBL] [Abstract][Full Text] [Related]  

  • 6. SRL172 (killed Mycobacterium vaccae) in addition to standard chemotherapy improves quality of life without affecting survival, in patients with advanced non-small-cell lung cancer: phase III results.
    O'Brien ME; Anderson H; Kaukel E; O'Byrne K; Pawlicki M; Von Pawel J; Reck M;
    Ann Oncol; 2004 Jun; 15(6):906-14. PubMed ID: 15151947
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical and immunological assessment of Mycobacterium vaccae (SRL172) with chemotherapy in patients with malignant mesothelioma.
    Mendes R; O'Brien ME; Mitra A; Norton A; Gregory RK; Padhani AR; Bromelow KV; Winkley AR; Ashley S; Smith IE; Souberbielle BE
    Br J Cancer; 2002 Feb; 86(3):336-41. PubMed ID: 11875694
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A randomized pilot study of SRL172 (Mycobacterium vaccae) in patients with small cell lung cancer (SCLC) treated with chemotherapy.
    Assersohn L; Souberbielle BE; O'Brien ME; Archer CD; Mendes R; Bass R; Bromelow KV; Palmer RD; Bouilloux E; Kennard DA; Smith IE
    Clin Oncol (R Coll Radiol); 2002 Feb; 14(1):23-7. PubMed ID: 11899903
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mycobacterium vaccae (SRL172): a potential immunological adjuvant evaluated in rat prostate cancer.
    Hrouda D; Souberbielle BE; Kayaga J; Corbishley CM; Kirby RS; Dalgleish AG
    Br J Urol; 1998 Dec; 82(6):870-6. PubMed ID: 9883227
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Impact of immunochemotherapy on survival of patients with metastatic renal cell carcinoma. A retrospective study comparing interferon-alpha-2a/vinblastine versus interferon-alpha-2a/interleukin-2/5-fluorouracil].
    May M; Helke C; Bock M; Hoschke B
    Urologe A; 2004 Sep; 43(9):1111-9. PubMed ID: 15232686
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunotherapy of advanced prostate cancer: a phase I/II trial using Mycobacterium vaccae (SRL172).
    Hrouda D; Baban B; Dunsmuir WD; Kirby RS; Dalgleish AG
    Br J Urol; 1998 Oct; 82(4):568-73. PubMed ID: 9806190
    [TBL] [Abstract][Full Text] [Related]  

  • 12. SRL172 (killed Mycobacterium vaccae) may augment the efficacy of trastuzumab in metastatic breast cancer patients.
    Altundag K; Mohamed AS; Altundag O; Silay YS; Gunduz E; Demircan K
    Med Hypotheses; 2005; 64(2):248-51. PubMed ID: 15607548
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical outcome of combined immunotherapy with interferon-alpha and low-dose interleukine-2 for Japanese patients with metastatic renal cell carcinoma.
    Miyake H; Kurahashi T; Takenaka A; Inoue TA; Fujisawa M
    Urol Oncol; 2009; 27(6):598-603. PubMed ID: 18818106
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lack of retroperitoneal lymphadenopathy predicts survival of patients with metastatic renal cell carcinoma.
    Vasselli JR; Yang JC; Linehan WM; White DE; Rosenberg SA; Walther MM
    J Urol; 2001 Jul; 166(1):68-72. PubMed ID: 11435825
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combined immunotherapy with low-dose IL-2 plus IFN-alpha for metastatic renal cell carcinoma: survival benefit for selected patients with lung metastasis and serum sodium level.
    Akaza H; Tsukamoto T; Fujioka T; Tomita Y; Kitamura T; Ozono S; Miki T; Naito S; Zembutsu H; Nakamura Y
    Jpn J Clin Oncol; 2011 Aug; 41(8):1023-30. PubMed ID: 21642665
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment with SRL172 (heat-killed Mycobacterium vaccae) inhibits progression of established experimental periodontal disease in Wistar rats.
    Brelvik T; Rook GA
    J Periodontal Res; 2002 Jun; 37(3):210-4. PubMed ID: 12113556
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The role of adjuvant immunotherapy after radical nephrectomy and prognostic factors in pT3N0M0 renal cell carcinoma.
    Jeon SH; Chang SG; Kim JI
    Anticancer Res; 1999; 19(6C):5593-7. PubMed ID: 10697624
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Age does not impair the efficacy of immunochemotherapy in patients with metastatic renal carcinoma.
    Atzpodien J; Wandert T; Reitz M
    Crit Rev Oncol Hematol; 2005 Sep; 55(3):193-9. PubMed ID: 16115777
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Subcutaneous interleukin-2 plus interferon alfa-2a in metastatic renal cancer: an outpatient multicenter trial.
    Vogelzang NJ; Lipton A; Figlin RA
    J Clin Oncol; 1993 Sep; 11(9):1809-16. PubMed ID: 8355047
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Immunotherapeutic treatment for metastatic renal carcinoma].
    Hidalgo Pardo F; Gutiérrez Sanz-Gadea C; Rebassa Llull MJ; García Bueno JM; Mus Malleu A; Losada González GP; Ozonas Moragues M
    Actas Urol Esp; 1998 Jan; 22(1):29-33. PubMed ID: 9542189
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.